<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672213</url>
  </required_header>
  <id_info>
    <org_study_id>17081704</org_study_id>
    <nct_id>NCT04672213</nct_id>
  </id_info>
  <brief_title>TXA in Spine Surgery</brief_title>
  <official_title>Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid in Patients at High Risk for Blood Transfusion After Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and&#xD;
      method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim&#xD;
      of the study is to determine whether or not repeated dosing of oral or a different method of&#xD;
      delivery like intravenous (IV) TXA reduces the post-operative reduction in hemoglobin,&#xD;
      hematocrit, number of transfusions, and postoperative blood loss following open spine&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open lumbar spine surgery is associated with the risk of moderate to significant blood loss.&#xD;
      Because TXA has been shown to significantly reduce the need for blood products during total&#xD;
      joint replacement, it is now the standard of care for these procedures at many institutions.&#xD;
      Oral and IV TXA have been found to be similarly efficacious in total joint replacements, but&#xD;
      oral TXA is cheaper and allows for ease of repeat dosing.&#xD;
&#xD;
      Although low preoperative hemoglobin is a risk factor for transfusion, no studies that have&#xD;
      compared standard single-dose oral or IV TXA dosing to repeated oral dosing of TXA in&#xD;
      patients undergoing open spine surgery. Therefore, the aim of the study is to determine&#xD;
      whether or not repeated dosing of oral or a different method of delivery like intravenous&#xD;
      (IV) TXA reduces the post-operative reduction in hemoglobin, hematocrit, number of&#xD;
      transfusions, and postoperative blood loss following open spine surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Number of subjects transfused blood products and units of blood transfused.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin/Hematocrit</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Postoperative reduction in hemoglobin and hematocrit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost comparison</measure>
    <time_frame>30 days</time_frame>
    <description>Cost differences resulted from differences in the blood transfusion rate, length of hospital stay, and management of complications as well as from the cost of the TXA itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Deep vein thrombosis (DVT), Pulmonary embolism (PE), return to the operating room within 30 days, superficial or deep infection, cerebrovascular accident, transient ischemic attack, or myocardial infarction</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Postoperative Blood Loss Following Spine Surgery</condition>
  <arm_group>
    <arm_group_label>No TXA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No preoperative, intraoperative, or postoperative tranexamic acid will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g IV TXA bolus will be given at the time of incision intraoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-Oral TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three 650 mg tablets of oral TXA 2 hours prior to incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full Oral TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three 650 mg tablets of oral TXA 2 hours prior to incision and three 650 mg tablets of oral TXA given each day for three days postoperatively (while in the hospital as an inpatient).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Intravenous or oral tranexamic pre- and/or postoperatively</description>
    <arm_group_label>Full Oral TXA</arm_group_label>
    <arm_group_label>IV TXA</arm_group_label>
    <arm_group_label>Pre-Oral TXA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient older than 18 years old and scheduled for an open posterior thoracolumbar&#xD;
             spinal fusion procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to TXA&#xD;
&#xD;
          -  Acquired disturbances of color vision&#xD;
&#xD;
          -  Refusal of blood products&#xD;
&#xD;
          -  pre-op use of anticoagulant therapy within five days before surgery&#xD;
&#xD;
          -  history of arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA)&#xD;
&#xD;
          -  pregnancy, breastfeeding&#xD;
&#xD;
          -  major comorbidities (such as severe ischemic heart disease [New York Heart Association&#xD;
             Class III or IV], previous myocardial infarction, severe pulmonary disease, renal&#xD;
             impairment, or hepatic failure)&#xD;
&#xD;
          -  patients who decline to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew W Colman, MD</last_name>
      <phone>312-432-2435</phone>
      <email>colman.research@rushortho.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew Colman</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

